

1  
2  
3 **Supplementary Materials**

4 **The *Penicillium chrysogenum* Q176 antimicrobial protein PAFC effectively**  
5 **inhibits the growth of the opportunistic human pathogen *Candida albicans***

6 **Jeanett Holzknicht<sup>1</sup>, Alexander Kühbacher<sup>1</sup>, Csaba Papp<sup>2</sup>, Attila Farkas<sup>3</sup>, Györgyi Váradi<sup>4</sup>,**  
7 **José F. Marcos<sup>5</sup>, Paloma Manzanares<sup>5</sup>, Gábor K. Tóth<sup>4,6</sup>, László Galgóczy<sup>3,7\*</sup> and Florentine**  
8 **Marx<sup>1\*\*</sup>**

9  
10 <sup>1</sup> Biocenter, Institute of Molecular Biology, Medical University of Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria;  
11 jeanett.holzknicht@i-med.ac.at, alexander.kuehbacher@i-med.ac.at, florentine.marx@i-med.ac.at

12 <sup>2</sup> Department of Microbiology, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, H-6726 Szeged,  
13 Hungary; papp.cs66@gmail.com

14 <sup>3</sup> Institute of Plant Biology, Biological Research Centre, Temesvári krt. 62, H-6726 Szeged, Hungary; farkasa8@brc.com,  
15 galgoczi@brc.hu

16 <sup>4</sup> Department of Medical Chemistry, Faculty of Medicine, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary;  
17 varadi.gyorgyi@med.u-szeged.hu, toth.gabor@med.u-szeged.hu

18 <sup>5</sup> Department of Food Biotechnology, Instituto de Agroquímica y Tecnología de Alimentos (IATA-CSIC), Consejo  
19 Superior de Investigaciones Científicas (CSIC), Paterna, E-46980 Valencia, Spain; pmanz@iata.csic.es,  
20 jmarcos@iata.csic.es

21 <sup>6</sup> MTA-SZTE Biomimetic Systems Research Group, University of Szeged, Dóm tér 8, H-6726 Szeged, Hungary;  
22 toth.gabor@med.u-szeged.hu

23 <sup>7</sup> Department of Biotechnology, Faculty of Science and Informatics, University of Szeged, Közép fasor 52, H-6726  
24 Szeged, Hungary; galgoczi@bio.u-szeged.hu

25  
26 Correspondence: \*galgoczi.laszlo@brc.hu; Tel. +36 62 599 600 (415) (L.G.); \*\*florentine.marx@i-med.ac.at; Tel. +43  
27 512 9003 (70207) (F.M.)

## 28 **Supplementary Experimental Procedures**

29

### 30 **Harvest of the fungal exudate**

31 *P. chrysogenum* colonies grown on 2×PcMM agar for 120 h at 25°C secreted exudate at the bottom of the  
32 colony after 96 h and then droplets appeared on top of the colony. The liquid underneath the colony was  
33 harvested with a sterile syringe by puncturing the colony and the droplets were collected with a sterile pipette  
34 tip (Figure S1). The samples were analyzed for the presence of PAFC, PAF and PAFB by Western blot.

35

### 36 **Proof of PeAfpC antibody binding of PAFC and Western blotting**

37 The detection of PAFC was tested in a Western blot using PeAfpC antibody. To exclude cross-reactivity, the  
38 *P. chrysogenum* AMPs PAF and PAFB were included, where indicated. Protein samples (0.5-5 µg per lane)  
39 were loaded onto an 18% (w/v) SDS-polyacrylamide gel, electrophoresed and blotted onto a 0.2 µm PVDF  
40 nitrocellulose membrane (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using the Trans-Blot Turbo  
41 Transfer system (Bio-Rad Laboratories Inc., Hercules, CA, USA). The blot was then blocked with blocking  
42 buffer (0.3% (v/v) Tween 80, 3% (w/v) skimmed milk powder in PBS (pH 7.4)) for 2 h at room temperature  
43 and incubated with IgG purified rabbit anti-PAF serum (1:500) [1], rabbit anti-PAFB serum (1:1000) [2] or  
44 rabbit anti-PeAfpC serum (1:2500) [3] in blocking solution (0.3% (v/v) Tween 80, 1.5% (w/v) skimmed milk  
45 powder in PBS (pH 7.4)) for 3 h at room temperature. The blot was washed in washing buffer (0.3% (v/v)  
46 Tween 80 in PBS (pH 7.4)) three times and incubated with blocking buffer containing the anti-rabbit IgG  
47 alkaline phosphatase secondary antibody (1:10000, Sigma-Aldrich, Vienna, Austria) up to 3 h at room  
48 temperature. After washing three times in washing buffer and once in ddH<sub>2</sub>O for 5 min, the blot was  
49 equilibrated with alkaline phosphatase substrate buffer (100 mM Tris-HCl (pH 8.3), 150 mM NaCl, 1 mM  
50 MgCl<sub>2</sub>) for 5 min. The signal was developed by addition of p-nitroblue tetrazolium (0.5% (v/v), Promega,  
51 Madison, WI, USA) and 5-bromo-4-chloro-3-indolyl phosphate (0.25% (v/v), Promega, Madison, WI, USA)  
52 in alkaline phosphatase substrate buffer until desired intensity of the protein bands was achieved. The reaction  
53 was stopped with ddH<sub>2</sub>O for 5 min at room temperature.

54

### 55 **Cloning of the PAFC expression plasmid**

56 A PAFC overexpression strain was generated as described in Sonderegger *et al.* (2016) [4]. Briefly,  
57 pSK275\_*pafB* [2] was digested with XmaI and BglII to excise the *pafB* gene and replace it with the *pafC* gene.  
58 The *pafC* gene was PCR amplified (Table S3) from *P. chrysogenum* Q176 wild-type genomic DNA with the  
59 primers *pafC\_fwd\_XmaI* and *pafC\_rev\_BglII* (Table S4), containing the restriction sites BglII at the 5' and  
60 XmaI at the 3' end, which were attached to the *pafC* gene fragment (Figure S2A). The *pafC* sequence was  
61 ligated into the BglII/XmaI digested pSK275\_*pafB* vector using the NEBuilder high assembly kit (New  
62 England Biolabs, Ipswich, MA, USA), resulting in the plasmid pSK275\_*pafC* where *pafC* was put under the  
63 regulation of the strong *paf* gene promoter (Figure S2B). The plasmid pSK275\_*pafC* was propagated in *E. coli*  
64 DH5α, isolated with Monarch Plasmid Miniprep Kit (New England Biolabs, Ipswich, MA, USA) and the  
65 nucleotide sequence of the *pafC* expression cassette was verified by Sanger sequencing (Eurofins Genomics,

66 Ebersberg, Germany). Large plasmid quantities for fungal transformation were purified with PureYield™  
67 Plasmid Midiprep Kit (Promega, Madison, WI, USA).

68

#### 69 **Transformation pSK275\_pafC into *P. chrysogenum***

70 To avoid co-expression of PAF, the NotI-linearized plasmid pSK275\_pafC was transformed into the *P.*  
71 *chrysogenum* Δ*paf* mutant strain [4] according to the protocol of Cantoral *et al.* (1987) [5] and Kolar *et al.*  
72 (1988) [6] and transformants were selected for resistance against 1 μg mL<sup>-1</sup> pyrithiamine hydrobromide  
73 (Sigma-Aldrich, St. Louis, MO, USA) on 1×*Pc*MM agar. The genomic DNA of conidia of growing colonies  
74 were then checked for the presence of the fungal resistance marker pyrithiamine (*ptrA*) with PCR  
75 (Supplementary Material, Table S3) using the primers *ptrA\_fwd* and *ptrA\_rev* (Supplementary Material, Table  
76 S4). Several positive transformants were selected, grown in 200 mL 1×*Pc*MM and the cell free supernatant  
77 was tested for PAFC expression with 18% (w/v) SDS-polyacrylamide gel electrophoresis and silver staining.

78

#### 79 **Fluorescence microscopy**

80 For localization studies with PAFC-Bd, 1×10<sup>5</sup> *Candida* cells were exposed to 1×IC<sub>90</sub> (2.5 μM) PAFC-Bd for 8  
81 h at 30°C with shaking at 160 rpm and then stained with the nuclei-specific dye Hoechst 33342 (Sigma-  
82 Aldrich, St. Louis, MA, USA) in PBS (20 μg mL<sup>-1</sup> final concentration) for 10 min at room temperature with  
83 shaking in the dark.

84 For the detection of iROS induction by PAFC, 1×10<sup>5</sup> *Candida* cells were incubated with 1×IC<sub>90</sub> (2.5 μM)  
85 PAFC for 8 h at 30°C and shaking at 160 rpm. Untreated cells and cells treated with nystatin (10 μg mL<sup>-1</sup>)  
86 (Sigma-Aldrich, St. Louis, MO, USA) were taken as negative and positive controls, respectively. The cells  
87 were then stained with the iROS-specific fluorescent dye H<sub>2</sub>DCFDA (Sigma-Aldrich, St. Louis, MO, USA) in  
88 PBS (final concentration of 5 μg mL<sup>-1</sup>), for 30 min at 30°C with shaking at 160 rpm.

89 Before microscopic analysis all samples were washed twice in PBS and mounted on glass slides for  
90 microscopic analysis with a Zeiss Axioplan fluorescence microscope, equipped with an AxioCam MRc camera  
91 using excitation/emission filters 265/420 nm for blue fluorescence and 500/535 nm for green fluorescence  
92 (Carl Zeiss GmbH, Oberkochen, Germany). Image editing was done with Axiovision (Carl Zeiss GmbH,  
93 Oberkochen, Germany), Fiji [7], GNU Image Manipulation Program (GIMP, version 2.8.10) and Microsoft  
94 Power Point (Microsoft Corp.).

95 **Supplementary Tables**

96

97 **Table S1.** Fungal and bacterial strains used in this study.

Organism	Specification	Source
<i>Candida albicans</i> <sup>fluS</sup>	fluconazole-sensitive	CBS 5982
<i>Candida albicans</i> <sup>fluR</sup>	22700, fluconazole-resistant	[8]
<i>Candida glabrata</i>		CBS 138
<i>Candida guilliermondii</i>		CBS 566
<i>Candida krusei</i>		CBS 573
<i>Candida parapsilosis</i>		CBS 604
<i>Escherichia coli</i> DH5 $\alpha$	F <sup>-</sup> <i>endA1 glnV44 thi-1 recA1</i> <i>relA1 gyrA96 deoR nupG</i> <i>purB20 <math>\phi</math>80dlacZ<math>\Delta</math>M15</i> $\Delta$ ( <i>lacZYA-argF</i> )U169, hsdR17( <i>r<sub>K</sub><sup>-</sup>m<sub>K</sub><sup>+</sup></i> ), $\lambda$ <sup>-</sup>	New England Biolabs, Ipswich, MA, USA
<i>Penicillium chrysogenum</i> Q176	wild-type	ATCC 10002
<i>Penicillium chrysogenum</i> $\Delta$ <i>paf</i>	$\Delta$ <i>paf::nat1</i>	[9]
<i>Penicillium chrysogenum</i> <sup>OEpafC</sup>	$\Delta$ <i>paf::nat1, pafC, ptrA</i> <sup>+</sup>	This study

98

99

100

101 **Table S2.** Composition of media and solutions used in this study.

Medium	Abbreviation	Composition/Company <sup>1</sup>
<i>Penicillium chrysogenum</i> minimal medium	1 $\times$ PcMM	0.3% NaNO <sub>3</sub> , 0.05% MgSO <sub>4</sub> $\times$ 7 H <sub>2</sub> O, 0.05% KCl, 0.005% FeSO <sub>4</sub> $\times$ 7 H <sub>2</sub> O, 2% D(+)-sucrose, 2.5% 1 M KPO <sub>4</sub> -buffer (pH 5.8), 0.1% trace elements solution PcMM
<i>Penicillium chrysogenum</i> minimal medium double concentrated	2 $\times$ PcMM	0.6% NaNO <sub>3</sub> , 0.1% MgSO <sub>4</sub> $\times$ 7 H <sub>2</sub> O, 0.1% KCl, 0.01% FeSO <sub>4</sub> $\times$ 7 H <sub>2</sub> O, 4% D(+)-sucrose, 2.5% 1 M KPO <sub>4</sub> -buffer (pH 5.8), 0.1% trace elements solution PcMM
Trace elements solution PcMM	-	0.1% FeSO <sub>4</sub> $\times$ 7 H <sub>2</sub> O, 0.9% ZnSO <sub>4</sub> $\times$ 7 H <sub>2</sub> O, 0.04% CuSO <sub>4</sub> $\times$ 5 H <sub>2</sub> O, 0.01% MnSO <sub>4</sub> $\times$ H <sub>2</sub> O, 0.01% H <sub>3</sub> BO <sub>3</sub> , 0.01% Na <sub>2</sub> MoO <sub>4</sub> $\times$ 2 H <sub>2</sub> O
Potato dextrose broth	PDB	Sigma-Aldrich, St Louis, MO, USA

102

<sup>1</sup>Percent values are given as weight per volume (w/v) for solids and volume per volume (v/v) for solutions.

103

104 **Table S3.** PCR conditions applied in this study<sup>§</sup>.

Step	Temperature	Time
Initial denaturation	94°C	30 seconds
33 cycles	98°C	10 seconds
	69°C*/70°C <sup>#</sup>	20 seconds* / 30 seconds <sup>#</sup>
	72°C	20 seconds* / 1 min 30 seconds <sup>#</sup>
Elongation	72°C	1 minutes* / 2 minutes <sup>#</sup>

105 <sup>§</sup>PCR reaction mix was prepared according to the Q5<sup>®</sup> High-Fidelity Polymerase reaction protocol (New England  
 106 Biolabs, Ipswich, MA, USA); \*PCR conditions for the *pafC* amplicon; <sup>#</sup>PCR conditions for the *ptrA* amplicon.

107

108


109 **Table S4.** Oligonucleotides used in this study.

Primer	Sequence 5'-3'	Amplicon
<i>pafC</i> _fwd_XmaI	ACC ATC CCG GGC TAG CAT CTG GCT CCC CC	
<i>pafC</i> _rev_BglII	CAT AAA GAT CTA TGA AGG TTA CTG CTC TCC TCT TCA CCC	<i>pafC</i> gene
<i>ptrA</i> _fwd	GCA CTG AAC CCA TTC GGG TAG TGA G	<i>ptrA</i> resistance
<i>ptrA</i> _rev	CGG TGT TCG TTC CCA GTC ATC G	cassette

110

111 **Supplementary Figures**


112



113

114


115 **Figure S1. Exudate formation of *P. chrysogenum* surface colonies on 2×PcMM agar. (A)** Droplets on top  
116 of the colony after cultivation for 120 h at 25°C. **(B)** 120 h-old surface colony after harvesting the exudate  
117 accumulated under the colony. The arrow indicates the puncture for the exudate harvest. **(C)** Footprints of  
118 droplets on top of the colony after incubation for 144 h at 25°C are indicated by an arrow. Scale bar, 5 mm.



119

120

121 **Figure S2. Cloning of the expression vector pSK275\_ *pafC*.** (A) Schematic representation of the *pafC* PCR  
 122 fragment (turquoise) with attached restriction sites BglII and XmaI (red). (B) Map of the expression plasmid  
 123 pSK275\_ *pafC* used for transformation of *P. chrysogenum*  $\Delta paf$ . The *pafC* gene expression cassette consists of  
 124 the *paf* promoter (5' *paf* promoter, yellow), the *pafC* gene fragment (*pafC*, turquoise) and the 3' terminator of  
 125 *paf* (3' *paf* UTR, green). The plasmid further contains the origin of replication (F1 ori, blue), the ampicillin  
 126 resistance gene (*ampR*, orange) and the pyrithiamine resistance gene (*ptrA*, red).



128

129

130


131

132

133


134

**Figure S3. Amino acid alignment of PAFC and orthologous AMPs. (A)** pre-pro sequence and **(B)** mature protein sequence of the *P. chrysogenum* PAFC [2], the *P. expansum* PeAfpC [3] and the *P. brevicompactum* BP [10] including the respective conservation between the sequences based on the ClustalW2 Multiple Sequence Alignment tool [11]. Conserved regions are marked with an asterisk, scale is 1-10. The  $\gamma$ -core motifs are framed in red. Color coding of amino acids according to ClustalX.



135  
136


137 **Figure S4. Ramachandran plot of the PAFC model.** Energetically allowed regions for backbone dihedral  
 138 angles  $\psi$  against  $\phi$  of the amino acid residues in PAFC according to the RAMPAGE server tool [12]. General  
 139 amino acids are depicted with a square, proline residues with a triangle and glycine residues with a cross.  
 140 Favored regions are indicated in dark orange for glycine, other amino acids in dark blue, allowed regions in  
 141 light orange for glycine and light blue for all other amino acids. Amino acids in energetically favored regions  
 142 are shown in black (95.2%), and in allowed regions in orange (4.8%). No amino acids are in the outlier region  
 143 (0%).



144

145


146 **Figure S5. Expression of *pafC*, *paf* and *pafB* in synchronized surface cultures of *P. chrysogenum* over a**  
 147 **time course of 12-48 h of incubation. (A)** Ten µg of total RNA was loaded on a 1.2 % (w/v) formaldehyde  
 148 agarose gel, blotted and hybridized with the respective gene specific digoxigenin-labelled probes [2] (upper  
 149 panel). Ethidium bromide stained 26S and 18S rRNA provide loading controls (lower panels). **(B)** Images of  
 150 synchronized surface cultures of *P. chrysogenum* grown on 1×PcMM over a time course of 12-48 h. The onset  
 151 of sporulation was at 24 h of incubation.



153

154


155 **Figure S6. Western blot analysis to prove the binding of the PeAfpC antibody to PAFC.** Per lane, 5  $\mu$ g  
156 of PeAfpC and PAFC were loaded on a 18% (w/v) SDS-polyacrylamide gel, size fractionated and transferred  
157 onto a nitrocellulose membrane. Polyclonal rabbit PeAfpC antibody (1:2500) and enzyme-linked secondary  
158 anti-rabbit IgG (1:10000, Sigma-Aldrich, St. Louis, MA, USA) were used for the detection of PAFC.  
159 Visualization of antigen-antibody complexes was performed with BCIP/NBT system (Promega, Madison,  
160 WO, USA). Low range rainbow marker (LRM) (GE Healthcare Life Sciences, Little Chalfont, UK) was used  
161 as size marker. The molecular weight (MW) marker bands of 3.5 kDa and 8.5 kDa are indicated and the MW  
162 of PAFC (6.6 kDa) is marked with an arrow.



163  
164


165 **Figure S7. Purification of recombinant PAFC.** (A) 18% (w/v) silver stained SDS-polyacrylamide gel  
 166 showing samples collected during the PAFC purification process. Lanes: (1) Crude 96-hours-old cell-free  
 167 supernatant; (2) column wash (25 mM NaCl); (3) eluted fraction 3 (100 mM NaCl); (4) eluted fraction 6 (100  
 168 mM NaCl) containing PAFC. PAFC is indicated by an arrow. (B) Reversed-phase high-performance liquid  
 169 chromatography analysis of PAFC. The PAFC specific peak is indicated by an arrow. (C) The protein identity  
 170 was confirmed with electro-spray mass spectrometry. The molecular mass in Da corresponding to PAFC  
 171 (oxidized form) is circled in red.

172



173  
174


175 **Figure S8. Fluorescence microscopy for the localization of nuclei and PAFC-Bd.** (A) *C. albicans*<sup>fluS</sup> and  
 176 (B) *C. albicans*<sup>fluR</sup> were exposed to 1×IC<sub>90</sub> PAFC-Bd (2.5 μM) for 8 h and then nuclei were stained with the  
 177 nuclei-specific dye Hoechst 33342 (20 μg mL<sup>-1</sup>) for 10 min in the dark before microscopic analysis. Cells  
 178 without PAFC-Bd treatment (untreated) were used as controls. The merged images show the nuclei-specific  
 179 and the PAFC-Bd fluorescent signals superimposed in the *Candida* cells visualized with brightfield  
 180 microscopy. One representative image out of three replicates is shown. BF = brightfield, PAFC-Bd = Bd-  
 181 labelled PAFC. Scale bar, 5 μm.



182

183

184 **Figure S9. Ion tolerance of PAFC.** The activity of  $1 \times IC_{90}$  ( $2.5 \mu M$ ) PAFC was tested on *C. albicans*<sup>fluS</sup> in the  
 185 presence of increasing concentrations (0 -10 mM) of NaCl, CaCl<sub>2</sub> and MgCl<sub>2</sub> in a microdilution broth assay.  
 186 *Candida* cells left untreated were used as growth control representing 100% growth. The mean  $\pm$  SD (technical  
 187 triplicate of one representative experiment out of two biological replicates) is shown. A two-sample Student's  
 188 t-test was applied to calculate the significant difference between the salt-treated samples compared to the  
 189 untreated controls (no PAFC) ( $p \leq 0.05$  and  $**p \leq 0.005$ ).



190  
191

192 **Figure S10. Hemolytic activity of PAFC tested with agar diffusion assay.** PAFC was added in 10  $\mu$ L  
193 aliquots containing 13  $\mu$ g protein on sterile filter discs on Columbia blood agar plates. Water was used as a  
194 negative control and 20% (v/v) Triton X-100 as a positive control for induction of hemolysis. The plates were  
195 incubated for 24 h at 37°C. One representative experiment out of two.

196 **Supplementary References**

197

- 198 1. Oberparleiter, C.; Kaiserer, L.; Haas, H.; Ladurner, P.; Andratsch, M.; Marx, F. Active internalization of the  
199 *Penicillium chrysogenum* antifungal protein PAF in sensitive *Aspergilli*. *Antimicrob Agents and Chemother* **2003**,  
200 47, 3598-3601, doi:10.1128/aac.47.11.3598-3601.2003.
- 201 2. Huber, A.; Hajdu, D.; Bratschun-Khan, D.; Gáspári, Z.; Varbanov, M.; Philippot, S.; Fizil, A.; Czajlik, A.; Kele, Z.;  
202 Sonderegger, C.; et al. New antimicrobial potential and structural properties of PAFB: a cationic, cysteine-rich  
203 protein from *Penicillium chrysogenum* Q176. *Sci Rep* **2018**, 8, 1751, doi:10.1038/s41598-018-20002-2.
- 204 3. Garrigues, S.; Gandía, M.; Castillo, L.; Coca, M.; Marx, F.; Manzanares, P.; Marcos, J.F.; Manzanares, P. Three  
205 antifungal proteins from *Penicillium expansum* : Different patterns of production and antifungal activity. *Front*  
206 *Microbiol* **2018**, 9, 2370, doi: 10.3389/fmicb.2018.02370.
- 207 4. Sonderegger, C.; Galgóczy, L.; Garrigues, S.; Fizil, Á.; Borics, A.; Manzanares, P.; Hegedüs, N.; Huber, A.; Marcos,  
208 J.F.; Batta, G.; et al. A *Penicillium chrysogenum*-based expression system for the production of small, cysteine-rich  
209 antifungal proteins for structural and functional analyses. *Microb Cell Fact* **2016**, 15, 192, doi: 10.1186/s12934-  
210 016-0586-4.
- 211 5. Cantoral, J.M.; Díez, B.; Barredo, J.; Alvarez, E.; Martín, J.F. High-frequency transformation of *Penicillium*  
212 *chrysogenum*. *Nat Biotechnol* **1987**, 5, 494-497, doi.org/10.1038/nbt0587-494.
- 213 6. Kolar, M.; Punt, P.J.; van den Hondel, C.A.; Schwab, H. Transformation of *Penicillium chrysogenum* using  
214 dominant selection markers and expression of an *Escherichia coli lacZ* fusion gene. *Gene* **1988**, 62, 127-134, doi:  
215 10.1016/0378-1119(88)90586-0.
- 216 7. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.;  
217 Saalfeld, S.; Schmid, B.; et al. Fiji: an open-source platform for biological-image analysis. *Nat Methods* **2012**, 9,  
218 676-682, doi: 10.1038/nmeth.2019.
- 219 8. Kovács, R.; Holzknecht, J.; Hargitai, Z.; Papp, C.; Farkas, A.; Borics, A.; Tóth, L.; Váradi, G.; Tóth, G.; Kovács, I;  
220 et al. *In vivo* applicability of *Neosartorya fischeri* antifungal protein 2 (NFAP2) in treatment of vulvovaginal  
221 candidiasis. *Antimicrob Agents Chemother* **2019**, 63, e01777-18, doi:10.1128/AAC.01777-18.
- 222 9. Hegedüs, N.; Sigl, C.; Zadra, I.; Pócsi, I., Marx, F. The *paf* gene product modulates asexual development in  
223 *Penicillium chrysogenum*. *J Basic Microbiol* **2011**, 51, 253-262, doi:10.1002/jobm.201000321.
- 224 10. Olsen, J.G.; Flensburg, C.; Olsen, O.; Bricogne, G.; Henriksen, A. Solving the structure of the bubble protein using  
225 the anomalous sulfur signal from single-crystal in-house Cu K $\alpha$  diffraction data only. *Acta Crystallogr D Biol*  
226 *Crystallogr* **2004**, 60, 250-255, doi: 10.1107/S0907444903025927.
- 227 11. Sievers, F.; Wilm, A.; Dineen, D.; Gibson, T.J.; Karplus, K.; Li, W.; Lopez, R.; McWilliam, H.; Remmert, M.;  
228 Söding, J.; et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal  
229 Omega. *Mol Syst Biol* **2011**, 7, 539, doi: 10.1038/msb.2011.75.
- 230 12. Lovell, S.C.; Davis, I.W.; Arendall, W.B., 3rd; de Bakker, P.I.; Word, J.M.; Prisant, M.G.; Richardson, J.S.;  
231 Richardson, D.C. Structure validation by C $\alpha$  geometry: phi, psi and C $\beta$  deviation. *Proteins* **2003**, 50, 437-  
232 450, doi:10.1002/prot.10286.
- 233